-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Neutral on Conmed, Raises Price Target to $50

Benzinga·10/29/2026 21:27:56
JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Neutral and raises the price target from $45 to $50.